Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cognitive Development During Adulthood01:30

Cognitive Development During Adulthood

709
Cognitive development continues throughout adulthood, undergoing significant shifts across early, middle, and late stages. Individual transition occurs from adolescent idealism to pragmatic and adaptable thinking in early adulthood. During this period, individuals learn to integrate personal beliefs with the recognition that other perspectives are equally valid. Exposure to the complexities of modern society, diverse experiences, and higher education contribute to this adaptive thought process,...
709
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

1.5K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.5K
Dementia01:30

Dementia

465
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
465
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists01:30

Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists

471
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
471
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

715
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
715
Intellectual Disability01:29

Intellectual Disability

551
Intellectual disability (ID) is a neurodevelopmental condition characterized by deficits in intellectual and adaptive functioning that manifest during the developmental period. This condition encompasses challenges in reasoning, memory, problem-solving, and learning, accompanied by impairments in everyday life skills, such as communication, self-care, and social interactions. Intellectual disability affects approximately 1% of the population in the United States, impacting an estimated 5...
551

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[Headache and cognitive impairment in patients with chronic cerebral ischemia].

Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova·2026
Same author

[Development of a diagnostic and treatment algorithm for anxiety associated with somatic pathology in patients in general clinical practice. Resolution of the expert council].

Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova·2025
Same author

[Comorbid anxiety disorders in patients with neurological pathology: current state of the problem and the role of etifoxine in treatment strategy].

Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova·2024
Same author

[Headaches in general medical practice].

Terapevticheskii arkhiv·2022
Same author

[Migraine in the real-life clinical practice: results of the observational study of diagnosis and treatment patterns in the urban population of the Russian Federation].

Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova·2022
Same author

[A role of cognitive and emotional factors in formation of pain].

Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova·2021

Related Experiment Video

Updated: Jan 2, 2026

A Machine Learning Approach to Design an Efficient Selective Screening of Mild Cognitive Impairment
12:18

A Machine Learning Approach to Design an Efficient Selective Screening of Mild Cognitive Impairment

Published on: January 11, 2020

7.9K

[Mild cognitive impairment: what's next?]

G R Tabeeva1

  • 1Sechenov First Moscow State Medical University, Moscow, Russia.

Zhurnal Nevrologii I Psikhiatrii Imeni S.S. Korsakova
|December 4, 2019
PubMed
Summary

Mild cognitive impairment research offers insights into predementia stages and potential reversibility of cognitive decline. Studying risk factors and subtypes may pave the way for novel dementia prevention and treatment strategies.

Keywords:
Alzheimer’s diseasedementiamild cognitive impairmentsubjective cognitive declinevascular cognitive impairmentvascular dementia

More Related Videos

The 4 Mountains Test: A Short Test of Spatial Memory with High Sensitivity for the Diagnosis of Pre-dementia Alzheimer's Disease
06:23

The 4 Mountains Test: A Short Test of Spatial Memory with High Sensitivity for the Diagnosis of Pre-dementia Alzheimer's Disease

Published on: October 13, 2016

33.6K
Dual-Task Stroop Paradigm for Detecting Cognitive Deficits in High-Functioning Stroke Patients
07:42

Dual-Task Stroop Paradigm for Detecting Cognitive Deficits in High-Functioning Stroke Patients

Published on: December 16, 2022

3.5K

Related Experiment Videos

Last Updated: Jan 2, 2026

A Machine Learning Approach to Design an Efficient Selective Screening of Mild Cognitive Impairment
12:18

A Machine Learning Approach to Design an Efficient Selective Screening of Mild Cognitive Impairment

Published on: January 11, 2020

7.9K
The 4 Mountains Test: A Short Test of Spatial Memory with High Sensitivity for the Diagnosis of Pre-dementia Alzheimer's Disease
06:23

The 4 Mountains Test: A Short Test of Spatial Memory with High Sensitivity for the Diagnosis of Pre-dementia Alzheimer's Disease

Published on: October 13, 2016

33.6K
Dual-Task Stroop Paradigm for Detecting Cognitive Deficits in High-Functioning Stroke Patients
07:42

Dual-Task Stroop Paradigm for Detecting Cognitive Deficits in High-Functioning Stroke Patients

Published on: December 16, 2022

3.5K

Area of Science:

  • Neurology
  • Gerontology
  • Cognitive Science

Background:

  • Mild cognitive impairment (MCI) represents a critical stage preceding dementia.
  • Understanding MCI is vital due to the high risk of dementia progression and the potential for cognitive recovery.
  • Cognitive decline trajectories in aging populations are diverse and require further investigation.

Purpose of the Study:

  • To explore the significance of mild cognitive impairment in predementia research.
  • To identify risk factors associated with the progression of cognitive impairment.
  • To investigate potential therapeutic avenues for MCI subtypes to improve clinical outcomes and slow disease progression.

Main Methods:

  • Longitudinal follow-up of patients with cognitive decline.
  • Analysis of risk factors for moderate cognitive impairment progression.
  • Exploration of treatment strategies for MCI subtypes.

Main Results:

  • Mild cognitive impairment research provides insights into predementia stages.
  • Risk factor identification opens new possibilities for dementia prevention.
  • Subtype-specific treatments show promise for symptom improvement and slowing progression, despite current drug therapy limitations.

Conclusions:

  • Mild cognitive impairment is a key area for understanding and potentially reversing cognitive decline.
  • Identifying risk factors and exploring targeted treatments are crucial for dementia prevention and management.
  • Further research into MCI subtypes holds promise for enhancing clinical symptoms and reducing the rate of cognitive decline.